Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.42 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.42 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1610929 | 0.83 | ALDH1A1 (0.36) | ALDH1A1CYP1A2CYP2C9CYP2C19ADRA2A | |
| SCHEMBL143456 | 0.80 | ALDH1A1 (0.50) | ALDH1A1CYP1A2CYP2C9CYP2C19ADRA2A | |
| SCHEMBL10399086 | 0.80 | ALDH1A1 (0.50) | ALDH1A1CYP1A2CYP2C9CYP2C19ADRA2A | |
| SCHEMBL367155 | 0.77 | ALDH1A1 (0.47) | ALDH1A1CYP1A2CYP2C9CYP2C19ADRA2A | |
| SCHEMBL21538667 | 0.77 | ALDH1A1 (0.56) | ALDH1A1CYP1A2CYP2C9CYP2C19ADRA2A | |
| SCHEMBL353568 | 0.77 | ALDH1A1 (0.56) | ALDH1A1CYP1A2CYP2C9CYP2C19ADRA2A | |
| SCHEMBL29367357 | 0.77 | ALDH1A1 (0.56) | ALDH1A1CYP1A2CYP2C9CYP2C19ADRA2A | |
| SCHEMBL128713 | 0.77 | ALDH1A1 (0.56) | ALDH1A1CYP1A2CYP2C9CYP2C19ADRA2A | |
| SCHEMBL335062 | 0.77 | ALDH1A1 (0.56) | ALDH1A1CYP1A2CYP2C9CYP2C19ADRA2A | |
| SCHEMBL29372643 | 0.77 | ALDH1A1 (0.56) | ALDH1A1CYP1A2CYP2C9CYP2C19ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8053598-B2 | Compounds, their preparation and use | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-11-08 | — | — | US | disclosed |
| EP-1745014-B1 | NOVEL COMPOUNDS, THEIR PREPARATION AND USE | HIGH POINT PHARMACEUTICALS LLC (US) | 2011-07-06 | — | — | EP | disclosed |
| US-7943612-B2 | Compounds that modulate PPAR activity, their preparation and use | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-05-17 | — | — | US | disclosed |
| US-20110087034-A1 | Organic Semiconductor Material | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2011-04-14 | — | — | US | disclosed |
| EP-2248818-A1 | ORGANIC SEMICONDUCTOR MATERIAL | Sumitomo Chemical Company, Limited (JP) | 2010-11-10 | — | — | EP | disclosed |
| US-20090048257-A1 | COMPOUNDS THAT MODULATE PPAR ACTIVITY, THEIR PREPARATION AND USE | HIGH POINT PHARMACEUTICALS, LLC | 2009-02-19 | — | — | US | disclosed |
| US-20090012171-A1 | Novel Compounds, Their Preparation and Use | NOVO NORDISK A/S (CZ) | 2009-01-08 | — | — | US | disclosed |
| EP-1999098-A2 | COMPOUNDS THAT MODULATE PPAR ACTIVITY, THEIR PREPARATION AND USE | High Point Pharmaceuticals, LLC (US) | 2008-12-10 | — | — | EP | disclosed |
| US-7273953-B2 | Process for producing arylamine | FUJIFILM FINECHEMICALS CO., LTD. (JP) | 2007-09-25 | — | — | US | disclosed |
| WO-2007101864-A2 | COMPOUNDS THAT MODULATE PPAR ACTIVITY, THEIR PREPARATION AND USE | HIGH POINT PHARMACEUTICALS, LLC (US) | 2007-09-13 | — | — | WO | disclosed |
| EP-1745014-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2007-01-24 | — | — | EP | disclosed |
| US-20060069287-A1 | Process for producing arylamine | FUJIFILM FINECHEMICALS CO., LTD. (JP) | 2006-03-30 | — | — | US | disclosed |
| WO-2005105736-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069287-A1 | Process for producing arylamine | TYR, AADAC, AOC2 | ALDH1A1 747/4885CYP1A2 51/4885CYP2C9 82/4885 |
| US-20090048257-A1 | COMPOUNDS THAT MODULATE PPAR ACTIVITY, THEIR PREPARATION AND USE | PPARD, PPARG, PPARA | ALDH1A1 1075/4885CYP1A2 623/4885CYP2C9 854/4885 |
| US-20090012171-A1 | Novel Compounds, Their Preparation and Use | PPARG, PPARD, PPARA | ALDH1A1 939/4885CYP1A2 527/4885CYP2C9 1068/4885 |
| US-20110087034-A1 | Organic Semiconductor Material | OR10J3, TST, OR51E2 | ALDH1A1 137/4885CYP1A2 125/4885CYP2C9 823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.